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Objectives: The aims of the present study were (1) to determine the proportion and characteristics of patients treated in Assertive Community
Treatment teams who achieve symptomatic remission (SR) and/or functional remission (FR) and (2) to explore the association between both
types of remission and (3) their bearing on quality of life (QoL).
Methods: Data comprised assessments from 278 patients who were repeatedly assessed using the Positive and Negative Syndrome Scale to
assess SR, the Health of the Nation Outcome Scales to assess FR, and a shortened version of the Manchester Short Assessment to assess
QoL. χ2 Tests and a logistic regression analysis were used to analyze the relation between patient and treatment characteristics and achieving
SR or FR. A Kruskal-Wallis test, Mann-Whitney U tests, and a logistic regression analysis were used to analyze the relationship between
remission status and QoL.
Results: After a mean treatment duration of 2.4 years, 26% met the criteria for SR and 30% for FR. Prescription of antipsychotic medication
was associated with achieving both SR and FR. Approximately half of the patients who achieved SR also achieved FR. Achieving FR was
associated with better QoL. Patients in SR did not have better QoL than did patients not in SR.
Conclusions: Remission of symptoms in patients treated in Assertive Community Treatment teams was not a prerequisite for FR or vice
versa. FR, not SR, was associated with better QoL.
© 2012 Elsevier Inc. All rights reserved.1. Introduction
Outcome in schizophrenia is a multidimensional construct,
including symptom level, functioning, and quality of life
(QoL) [1-4]. Symptomatic remission (SR) is often used to
measure the success of treatment and can be defined as a state
characterized by a fall in the severity of symptoms with a low
to mild symptom threshold over a meaningful period [5-7].
Andreasen et al [5] proposed criteria for SR as a low to mild
symptom level (positive, negative, and disorganized symp-
toms) for more than 6 months, with no impact on the⁎ Corresponding author. Bavo-Europoort, Prins Constantijnweg 48-54,
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doi:10.1016/j.comppsych.2012.05.001individual's behavior. Outcome can also be assessed in terms
of functional remission (FR) [8], although, to date, no
generally accepted definition of FR exists [6,9-11]. Defining
FR may be more difficult because there is no societal norm or
clear reference for the level of functioning in daily life (eg,
about being employed, social role, independent living, and the
quality of social contacts) [6,12]. Some authors propose that
FR in patients with psychotic disorder consists of adequate
functioning in a variety of important life domains including
social relationships, productive activities, activities of daily
living, and living conditions [6]. Wunderink et al [8] suggest
that FR should reflect appropriate social role functioning in the
main domains of everyday life, such as occupation, social
relationships, citizenship, and partnership. Based on similar-
ities in the descriptions of FR, we propose to define FR as
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functioning, daily life activities, and living conditions.
To date, it is unknown whether SR is a prerequisite for FR
and which one of the 2 is associated with QoL. Two recent
studies [8,13] showed that patients meeting the SR criterion
did have better levels of functioning than did patients not in
remission. However, there was no evidence that achieving SR
was an essential precondition for appropriate functioning.
Results of studies on the associations between SR and/or
FR and QoL are inconsistent [6,8,14-17]. Some authors
suggest that there is no clear relation between the level of
functioning or symptoms and QoL [6,8], whereas others
have argued that the severity of the symptoms and the level
of social functioning are of importance for QoL [14-17].
Therefore, in this study, we determined the proportion of
patients treated in ACT teams who achieved SR and/or FR,
examined which patient and treatment characteristics were
associated with achieving SR and/or FR, and explored the
association between both types of remission and their
bearing on QoL.2. Methods
2.1. Setting and patients
The study involved patients with psychotic disorder from 7
ACT teams in the city of Rotterdam, the Netherlands. Criteria
for treatment by anACT teamwere (1) age 18 years or greater;
(2) having a severemental illness, usually a psychotic disorder,
with or without a comorbid substance use disorder (SUD); and
(3) a lack ofmotivation for regular treatment at the start ofACT
that made assertive outreach necessary.
2.2. Data collection
Data from this study were obtained as part of a routine
outcome-monitoring (ROM) procedure. The ROM assess-
ments included several instruments and were planned every
6 months. The assessments were completed by independent
raters (mostly psychologists) and were used in clinical
practice to discuss treatment progress with the patient.
Routine outcome-monitoring data collection was approved
by the Dutch Committee for the Protection of Personal Data.
Data for the present study were used anonymously. In
addition to the ROM assessments, the following data were
collected: sex, age, ethnicity (country of birth), education
level, age of first contact with mental health services,
Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition diagnoses (as made by the psychiatrist of the
ACT team), being prescribed antipsychotic medication (yes
or no), and duration of treatment in ACT.
2.3. Instruments
2.3.1. Assessment of SR
To assess SR, we used 8 items of the Positive and
Negative Syndrome Scale (PANSS) proposed by theRemission in Schizophrenia Working Group [5]. Sympto-
matic remission was defined as scores of 3 or lower during a
6-month period or more for 8 items: P1 (delusions), P2
(conceptual disorganization), P3 (hallucinatory behavior),
N1 (blunted affect), N4 (social withdrawal), N6 (lack of
spontaneity), G5 (mannerisms/posturing), and G9 (unusual
thought content).
2.3.2. Assessment of FR
We have proposed to define FR as no more than mild
disabilities in social functioning, daily life activities, and
living conditions. It should be emphasized that there is no
generally accepted definition of FR and, thus, no specific
instrument to assess it. In the present study, we used 3 items
of the Health of the Nation Outcome Scales (HoNOS) to
assess FR [18,19]. The HoNOS was originally developed as
a standardized assessment tool for routine use by mental
health services. It consists of 12 clinician-rated scales, each
using 5 points from 0 (no problem) to 4 (severe/very severe).
The psychometric properties of the English and Dutch
HoNOS scores have been found to be acceptable [18,19].
The following 3 items were used to assess FR: (1) everyday
social functioning (item 9: relationship problems); (2)
activities of daily living and complex skills (item 10:
problems of daily living), such as budgeting, organizing life,
occupation recreation, mobility, the use of transport, and
shopping; and (3) housing (item 11: problems with living
conditions). Patients achieved FR if their disabilities in social
functioning, daily life activities, and living conditions were
no more than minimal to mild—in other words, if these
HoNOS items were scored 2 or lower during a period of 6
months or more.
2.3.3. Assessment of QoL
The QoL scale of the cumulative needs for care monitor
was used to measure subjective QoL [20]. This instrument
was based on the Manchester Short Assessment (MANSA)
of QoL scale [21]. The scale consists of 6 items [22]
including financial situation, accommodation, relationship
with others, physical health, psychological health, and life as
a whole, which were rated on a 7-point scale (1 [“Couldn't be
worse”] to 7 [“Couldn't be better”]).
2.3.4. Analyses
SPSS version 15.0 was used for all analyses (SPSS,
Chicago, Illinois). First, we determined the proportion of
patients who had been in SR and FR over the last 2
assessments. Using Pearson χ2 test, we compared patient
characteristics: sex, age (18-30, 30-40, 40-50, N50 years),
ethnicity (born in the Netherlands or elsewhere), education
level (none, elementary, lower high school and over),
comorbid SUD (yes or no), and treatment characteristics:
prescription of antipsychotic medication (yes or no) and
treatment duration (0-1, 1-2, 2-3, N3 years of ACT before their
assessment) between patients achieving SR and/or FR vs those
who did not. We also used Pearson χ2 test to explore the
relationship between patients achieving SR and FR.
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performed, including baseline values and all patient and
treatment characteristics as predictors of SR and FR. Note
that PANSS baseline values were not included because they
were not available. Logistic regression was carried out
starting with a stepwise forward selection, predictors
required a probability value of P b .25 for entry into the
model, and then subsequently, the predictors were removed
at a probability value of P N .05 using the stepwise backward
elimination procedure and a log likelihood test. Next
interaction terms were calculated, followed by a forward
stepwise (P N .25) and backward elimination (P N .05)
procedure of these interaction terms [23].
To explore the relationship between remission (SR and
FR) and their bearing on QoL, we analyzed the relationship
between remission status and QoL (total score) during the
last ROM assessment using a Kruskal-Wallis test and Mann-
Whitney U tests. Afterward, a logistic regression analysis
was performed, including baseline QoL scores and remission
status (SR and FR) as predictors of QoL (dichotomized via
median split).Table 1
Symptomatic and FR in 278 patients after a mean (SD) of 2.4 (1.5) years of
treatment in ACT teams
FR, n (%) NFR, n (%) Total, n (%)
SR n (%) 38 (R 52.8%,
C 45.2%)
34 (R 47.2%,
C 17.5%)
72 (R 100%,
C 25.9%)
NSR n (%) 46 (R 22.3%,
C 54.8%)
160 (R 77.7%,
C 82.5%)
206 (R 100%,
C 74.1%)
Total n (%) 84 (R 30.2%,
C 100%)
194 (R 69.8%,
C 100%)
278 (R 100%,
C 100%)
NSR, no SR; NFR, no FR; n, number of patients; R, row percentage; C,
column percentage.3. Results
3.1. Patients
Within all 7 ACT teams, a total of 519 patients were
diagnosed as having a psychotic disorder. Routine outcome-
monitoring outcome data (2 repeated complete HoNOS and
PANSS assessments) were obtained from 278 patients,
representing 54% of all ACT patients with a psychotic
disorder. Based on the patient characteristics, these patients
appeared to be representative for all ACT patients with a
psychotic disorder, as we observed that the only statistical
significant difference between these patient groups was that
there were more male patients in our patient selection (82%
in the ROM group and 77% in the total group). We observed
no other statistically significant differences with respect to
age, ethnicity, or education level.
Most patients were male (82.4%) and had a mean (SD)
age of 41.4 (10.8) years. Only 44.2% were born in the
Netherlands. Diagnosis for all patients included in the study
was schizophrenia or other psychotic disorder. Forty-nine
percent were also diagnosed as having a comorbid SUD. The
mean (SD) treatment duration from the start of ACT was 2.4
(1.5) years, and the first contact with mental health services
started about a decade before entering in ACT (mean ± SD,
10.4 ± 9.0 years). The period between the 2 last consecutive
ROM assessments, which constituted the remission assess-
ment period, consisted of an average (SD) timeframe of 9.6
(4) months.
3.2. Proportions of symptomatic and FR (Table 1)
Symptomatic remission was achieved by 72 (26%) of the
278 patients, and 84 patients (30%) met the criteria for FR;160 patients (58%) achieved neither SR nor FR, and 38
patients (14%) achieved both SR and FR.
Of the 72 patients in SR, 38 (53%) also met the criteria for
FR; of the 84 patients in FR, 38 (45%) were also in SR
(Table 1). These data do not suggest a sequential relationship
between SR and FR, indicating that SR and FR do not seem to
be prerequisites for one another in this sample. The χ2 test for
the association between SR and FR (χ2 = 23.457, df = 1,
P b .001), however, showed that the proportion of patients in
SR who achieved FR (53%) differed from the proportion of
patients who did not achieve SR but achieved FR (22%) (odds
ratio, 3.887; 95% confidence interval [CI], 2.205-6.854).
Table 2 presents patient characteristics and their associ-
ations with SR and FR, respectively. These analyses showed
that the presence of an SUD and the prescription of
antipsychotics were associated with achieving SR. The
prescription of antipsychotics was also associated with
achieving FR. Logistic regression analyses (Table 3) showed
that only the prescription of antipsychotics remained as an
independent predictor of achieving both SR and FR.
3.3. Remission and QoL
Patients who were in SR (irrespective of FR) had higher
QoL scores than did patients who were not in SR (z = −2.338,
P = .019). The same was found concerning patients in FR
(irrespective of SR), also reporting a significantly higher
QoL compared with those who were not in FR (z = −4.376,
P b .001). When patients were divided into 4 groups—(1)
SR plus FR, (2) SR but no FR, (3) FR but no SR, and (4) no
SR plus no FR—they showed significant differences in
QoL total scores (Kruskal-Wallis test: χ2 = 21.203, df = 3,
P b .001). Further analyses showed that patients who were
both in FR and in SR (group 1) had better QoL scores
compared with patients who were in neither FR nor SR
(group 4) (z = −4.107, P b .001). However, there was no
difference in QoL between patients who were only in SR
(group 2) and those who were neither in SR nor FR (group 4)
(z = −0.552, P = .581). Interestingly, patients only in FR
(group 3) had better QoL than did patients who were neither
in FR nor SR (group 4) (z = −2.825, P = .005). A logistic
regression analysis confirmed these findings indicating that
only FR was independently associated with QoL (β = 2.584;
P = .011; 95% CI, 1.248-5.349) (Table 4).
Table 2
Characteristics of patients achieving symptomatic and FR
N = 278 (%)a n (%)b, in SR n (%)b, not in SR χ² SR n (%)b, in FR n (%)b, not in FR χ² FR
Sex
Male 229 (82.4) 59 (25.8) 170 (74.2) NS 69 (30.1) 160 (69.9) NS
Female 49 (17.6) 13 (26.5) 36 (73.5) 15 (30.6) 34 (69.4)
Age (y)
18-30 50 (18) 18 (36) 32 (64) P b .1 21 (42) 29 (58) P b .1
30-40 78 (28.1) 22 (28.2) 56 (71.8) 25 (32.1) 53 (67.9)
40-50 84 (30.2) 23 (27.4) 61 (72.6) 26 (31) 58 (69)
N50 64 (23) 9 (14.1) 55 (85.9) 12 (18.8) 52 (81.3)
Missing 2 (0.7)
Ethnicity
Native 123 (44.2) 31 (25.2) 92 (74.8) NS 34 (27.6) 89 (72.4) NS
Nonnative 155 (55.8) 41 (26.5) 114 (73.5) 50 (32.3) 105 (67.7)
Level of education
None 26 (9.4) 8 (30.8) 18 (69.2) NS 6 (23.1) 20 (76.9) NS
Elementary 38 (13.7) 11 (28.9) 27 (71.1) 12 (31.6) 26 (68.4)
Lower and over 161 (57.9) 42 (26.1) 119 (73.9) 48 (29.8) 113 (70.2)
Missing 53 (19.1)
Substance use
SUD 137 (49.3) 43 (31.4) 94 (68.6) P b .05 44 (32.1) 93 (67.9) NS
No SUD 141 (50.7) 29 (20.6) 112 (79.4) 40 (28.4) 101 (71.6)
Medication use
Prescription of AP 202 (72.7) 60 (29.7) 142 (70.3) P b .05 73 (36.1) 129 (63.9) P b .05
No prescription of AP 74 (26.6) 11 (14.9) 63 (85.1) 11 (14.9) 63 (85.1)
Missing 2 (0.7)
Treatment duration (y)
0-1 57 (20.5) 15 (26.3) 42 (73.7) NS 22 (38.6) 35 (61.4) NS
1-2 70 (25.2) 18 (25.7) 52 (74.3) 20 (28.6) 50 (71.4)
2-3 62 (22.3) 15 (24.2) 47 (75.8) 16 (25.8) 46 (74.2)
N3 87 (31.3) 23 (26.4) 64 (73.6) 26 (29.9) 61 (70.1)
Missing 2 (0.7)
χ², Pearson χ² test; AP, antipsychotics.
a Column percentage.
b Row percentage.
able 3
ogistic regression analyses for the association between demographic
ariables, SUD, and medication use and SR and FR, respectively
95% CI for Exp(B)
β (SE) Lower Exp(B) Upper
R
Constant −1.745 (0.327)⁎ – 0.175 –
Prescription of
antipsychotic medication
0.884 (0.361)† 1.192 2.42 4.912
R
Constant −2.171 (0.356)⁎ – 0.114 –
Prescription of
antipsychotic medication
1.069 (0.37)⁎ 1.409 2.911 6.013
Baseline FR 1.341 (0.284)⁎ 2.193 3.823 6.664
R: R2 = 0.036 (Nagelkerke), Hosmer and Lemeshow goodness of fit:χ² = –,
= –; FR: R2 = 0.171 (Nagelkerke), Hosmer and Lemeshow goodness of fit:
² = 4.556, P = .102.
⁎ P b .01.
† P b .05.
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4.1. Remission frequencies
Our results showed that 26% of the patients achieved SR
and 30% achieved FR after a mean of 2½ years of ACT.
Being prescribed antipsychotic medication was associated
with achieving SR and FR. Functional remission, not SR,
was associated with QoL.
4.2. Symptomatic and FR
In our study, the prescription of antipsychotic medication
was related to achieving both SR and FR. It may be that the
use of medication increases the chance of achieving SR and
FR or that those patients accepting medication have a better
prognosis, independent of the medication itself. The
observational design of the present study does not allow us
to determine causality.
On average, SR rates in patients from our study were
slightly inferior to those found by Shida et al [24] and
Lambert et al [10], who found that 1 in 3 of their patients was
in SR after a period of about 1 year. A study in first-episode
patients reported 52% SR over a 2-year follow-up [8]. Otherstudies even reported SR rates of 60% over 3 to 5-year
periods [25-27] and of 66% over a 2-year period [28]. These
discrepancies are likely to be related to the duration of
follow-up, treatment history and patient characteristics.T
L
v
S
F
S
P
χ
Table 4
QoL total scores in ACT patients with or without symptomatic or FR
QoL total score FR, median (IQR) NFR, median (IQR)
SR 33 (31-37) 29 (24-34)
NSR 32 (28-35) 28 (22-34)
NSR, no SR; NFR, no FR; IQR, interquartile range.
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medication adherence, possibly leading to a relatively worse
outcome. Also, our patient sample was older as compared
with the study using first-episode patients. With regard to the
possible impact of age, several factors may negatively
influence SR. First, the impact of prolonged (untreated)
illness and, second, higher age may reflect a filtering of
chronically difficult to engage patients in an ACT team.
Most patients treated in our ACT teams were in contact with
mental health services for more than a decade. Interestingly,
we found approximately the same FR rates as compared with
the study by Wunderink and colleagues [8], who found FR
rates of 26.4% after a 2-year period in first-episode patients
using the Groningen Social Disabilities Schedule (GSDS).
Other studies showed different proportions of patients
achieving FR. For example, one study by San and colleagues
[29] using a restrictive threshold of at least 81 points on the
Global Assessment of Functioning (GAF) scale reported that
social functioning was adequate in only 10.2% of all patients
with schizophrenia. Another study using the World Health
Organization Disability Assessment Schedule showed that
only 14% of patients with schizophrenia had no functional
disability after 15 years of follow-up [30]. In the present
study, however, we allowed for some minimal disability, so
the incongruence between these studies is likely to be related
to the use of different scales and definitions of FR, which
may have affected the remission rates [31]. Therefore, we
were not able to make valid comparisons with other studies.
We found no evidence of a temporal sequence for SR
after FR because more than half of the patients who achieved
SR also achieved FR and almost half the patients who
achieved FR also achieved SR. If a temporal sequence would
have been the case, more patients who achieved SR would
also have achieved FR or vice versa. This is only partly in
line with the assumptions of Weiden and Zygmunt [32] and
Priebe [4], who suggested that the presence of more
symptoms is associated with worse functioning. Based on
our data, however, it does not seem necessary to focus on
achieving SR first to achieve FR.
4.3. Remission and QoL
Patients who achieved FR, irrespective of SR, reported
better QoL than did patients who did not achieve FR.
Achieving SR without FR, however, was not associated with
a better QoL. The association of FRwithQoL suggests that FR
is a desirable treatment goal for patients, family, and clinicians.
These results are in partial disagreement with those of
Wunderink et al [8], who found that neither SR nor FR wasassociated with QoL. This discrepancy may be caused by the
levels of QoL in their sample of patients with first-episode
psychosis, which were generally much higher than ours.
Although Harvey and Bellack [6] suggest that “subjective
well-being does not have a clear correlational relationship
with other symptomatic and functional features of the
illness,” our results indicate that FR is associated with better
QoL, but that SR is not. By showing that SR tends to be of
less importance for patients' well-being than FR, our results
thus contrast with those of other studies [14-17,33].5. Limitations
Our results were based on 54% of all ACT patients with a
psychotic disorder. Although we did not find statistical
differences between both patient groups, except for sex, the
generalizability of the results to all ACT patients treated in
our center remains unknown. Also, our patient group
differed from the patient groups in other studies, making it
difficult to compare results, as stated above.
Another limitation of the work presented here is the
missing data in our study. First, we had no data on PANSS
assessments at baseline. Therefore, the true relation between
patient and treatment characteristics and SR could not be
properly assessed because we were not able to adjust for
baseline values of SR. Second, the missing rate of self-
reports on QoL was high (38.8%). We found no evidence of
a relation between the missing self-reports and socio-
demographic variables, although it is important to acknowl-
edge that patients with missing self-reports tend to have more
severe problems (FR). This means that the differences found
in QoL scores between patients in FR and those not in FR
may have been be underestimated.
An important conceptual limitation of our study is that we
used a specific definition of FR, based on 3 items of the
HoNOS. Therefore, we acknowledge that our assessment of
FRwas a rather crudemeasure for FR. Although this definition
is in line with the proposed criteria of FR [6,8], other studies
used other scales for assessing FR. Using the HoNOS,
however, has the advantage that this scale is widely used in
clinical practice in many countries and easy to administer. In
doing so, we feel that it is important to emphasize and
underline the expert opinion ofMausbach and colleagues [34],
who argue that we should try to use existing measures for
assessing functioning that are already in routine use. New
instruments with the sole purpose of measuring FR will
increase the risk that these instruments will be used only in
research but not in clinical practice. For this reason, we believe
that HoNOS is an appropriate instrument to assess FR.
Apart from the question of which instrument to use for
measuring FR (eg, the GAF, World Health Organization
Disability Assessment Schedule, GSDS, HoNOS or another
instrument), differences in cutoff levels are also important. We
defined FR as the 3 relevant HoNOS items scoring 2 or lower
(mild severity). However, FR might also be operationalized
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lower (minimal severity). In that case, only 2.3% of our
patients would have achieved FR (implying no or minimal
disabilities). Using those criteria would mean that FR is nearly
unachievable for patients receiving ACT, and therefore, these
stringent criteria do not seem appropriate to assess FR.
Because we found higher FR rates than in other studies
[29,30], this may suggest that our definition of FR was less
stringent. In the absence of a consensus definition of FR, this
remains unknown. We believe that our definition included
important life domains (social functioning, daily life activities,
and living conditions). It may be that when FR would be
defined more stringently, for example, as having work, living
independently, and having an appropriate social role, the
proportion of patients achieving FR might be lower. After all,
anyone in a job will plainly be hampered by severe psychotic
symptoms. Thus, our outcomes concerning FR rates and its
associations with SR are best understood as the result of the
operationalization of FR, being proper housing, self-care, and
social contacts. Following from this, it is clear that different
assessment methods or cutoff criteria can result in discrepant
findings (eg, 2.3% achieving FR and a different relation
between FR and SR). However, we feel that it is very difficult
and complex to create specific FR norms because no absolute
reference exists and because these norms may be related to
factors such as age or a downward economic situation.6. Conclusions
Symptomatic remission was achieved by 26% of ACT
patients after a mean period of 2½ years, and 30% reached
FR. Symptomatic remission did not seem to be a prerequisite
for FR or vice versa. Patients who achieved FR, irrespective
of SR, reported better QoL than those who did not,
supporting the choice of FR as a desirable treatment goal
for patients, family, and clinicians.
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